Search filters

Filters
Clear All

Phase

  • 2
  • 4
  • 2
  • 4
  • 13
  • 5
  • 13

Found 13 Amyloidosis trials

A listing of Amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Early Diagnosis of TTR Amyloid

Early Diagnosis of TTR Amyloid

40-75 years
All genders
Interventional
The purpose of this study is to find out if we can detect a disease of the heart called cardiac transthyretin (TTR) amyloidosis early. People develop cardiac TTR amyloidosis due to an accumulation of a transthyretin protein in the heart. This can happen as part of an aging process (wild …
 A Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

A Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

18-82 years
All genders
Phase 3
Interventional
A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. For those with : a. Stage 1 or Stage 2 according to the Familial Amyloid Polyneuropathy (FAP) or Coutinho Stage b. Documented genetic mutation in the TTR gene …

Expanded Access Protocol to Provide Patisiran to Patients with Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) with Cardiomyopathy

All genders
This patisiran expanded access protocol (EAP) is an open-label, multicenter, single-arm study designed to provide pre-approval access to investigational patisiran for patients with ATTR amyloidosis with cardiomyopathy who, at baseline, have an inadequate response to or cannot tolerate standard of care. An intravenous infusion of study drug (patisiran 0.3 mg/kg) …
 HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

18-85 years
All genders
Phase 3
Interventional
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period.
 ConTTRibute: Global Observational Multicenter Long-Term Study of Patients with Transthyretin (TTR)-Mediated Amyloidosis

ConTTRibute: Global Observational Multicenter Long-Term Study of Patients with Transthyretin (TTR)-Mediated Amyloidosis

18-99 years
All genders
Phase 3
This is a prospective global multicenter long-term observational study designed to document the clinical outcomes of patients with hereditary transthyretin-mediated amyloidosis or wild-type transthyretin-mediated amyloidosis and the safety of patisiran (Onpattro) when used in patients with ATTRv amyloidosis. This is data collection study only and no study medication no visits …
 A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

18-99 years
All genders
Phase 3
Interventional
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous …
 TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)

TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)

18-99 years
All genders
Phase 4
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine …

Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients with Light Chain Amyloidosis using Positron Emission Tomography (PET/CT)

All genders
We plan to enroll up to 25 (target of 20 fully evaluable) adult subjects in this study who have an established diagnosis of advanced cardiac amyloidosis (AL). Subjects will be included in 2 subject cohorts of approximately 10 subjects each. In one cohort positron emission tomography/computed tomography (PET/CT) imaging will …

AT-02-003 Open-label Extension Study

All genders
To assess the long-term safety and tolerability of AT-02 in subjects with Systemic Amyloidosis. Incidence, frequency, and severity of treatment-emergent adverse events (TEAEs) and severity of treatment-emergent serious adverse events (TESAEs) Change from baseline in clinical laboratory values, electrocardiograms (ECGs), physical examinations, and vital signs Change from baseline in biomarkers …
1 - 10 of 13